首页 > 最新文献

In vivo最新文献

英文 中文
Establishing a Mandibular Osteosarcoma Model in SD Rats Using Tissue Block Transplantation. 利用组织块移植在 SD 大鼠中建立下颌骨骨肉瘤模型
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13743
Lanlan Zhang, Jiaoyan Liu, Hongrong Zhang, Yemei Qian, Liqin Zhang, Weihong Wang

Background/aim: To investigate the feasibility of establishing a mandibular osteosarcoma model in Sprague-Dawley (SD) rats using tissue block transplantation, providing a foundational model for osteosarcoma research.

Materials and methods: Fourteen male SD rats, 3 weeks old and SPF grade, were randomly divided into a control group (n=4) and a mandibular osteosarcoma group (n=10). Using tissue block transplantation, UMR106 cell-induced tumor tissues were transplanted subcutaneously into the left mandibular marrow cavity of the SD rats. Observations included behavioral changes, weight variations, tumor growth, and tumor formation rate. Bone changes were monitored via micro-CT scanning, and histological analysis was conducted using HE staining.

Results: Two weeks post-transplantation, the mandibular osteosarcoma group exhibited significant left facial swelling, malocclusion, eating difficulties, and weight loss compared to the control group. The tumor formation rate was 80% (8/10). Micro-CT scans indicated significant bone destruction in the osteosarcoma group. HE staining revealed high cellular atypia and pathological mitoses in both subcutaneous and mandibular osteosarcoma cells, with no notable abnormalities in lung tissues.

Conclusion: Tissue block transplantation is a viable method to establish a mandibular osteosarcoma model in SD rats. This method is simple, with a high tumor formation rate, providing an ideal animal model for mandibular osteosarcoma research.

背景/目的:研究利用组织块移植在Sprague-Dawley(SD)大鼠中建立下颌骨骨肉瘤模型的可行性,为骨肉瘤研究提供基础模型:将14只3周大、SPF级的雄性SD大鼠随机分为对照组(4只)和下颌骨骨肉瘤组(10只)。采用组织块移植法,将 UMR106 细胞诱导的肿瘤组织皮下移植到 SD 大鼠的左下颌骨骨髓腔中。观察指标包括行为变化、体重变化、肿瘤生长和肿瘤形成率。通过显微 CT 扫描监测骨质变化,并使用 HE 染色进行组织学分析:移植后两周,与对照组相比,下颌骨骨肉瘤组表现出明显的左面部肿胀、咬合不正、进食困难和体重下降。肿瘤形成率为 80%(8/10)。显微 CT 扫描显示,骨肉瘤组的骨质破坏明显。HE染色显示皮下和下颌骨骨肉瘤细胞均有高度细胞不典型性和病理性有丝分裂,而肺组织无明显异常:结论:组织块移植是建立SD大鼠下颌骨骨肉瘤模型的可行方法。结论:组织块移植是在 SD 大鼠体内建立下颌骨骨肉瘤模型的一种可行方法,该方法操作简单,肿瘤形成率高,为下颌骨骨肉瘤研究提供了一种理想的动物模型。
{"title":"Establishing a Mandibular Osteosarcoma Model in SD Rats Using Tissue Block Transplantation.","authors":"Lanlan Zhang, Jiaoyan Liu, Hongrong Zhang, Yemei Qian, Liqin Zhang, Weihong Wang","doi":"10.21873/invivo.13743","DOIUrl":"10.21873/invivo.13743","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the feasibility of establishing a mandibular osteosarcoma model in Sprague-Dawley (SD) rats using tissue block transplantation, providing a foundational model for osteosarcoma research.</p><p><strong>Materials and methods: </strong>Fourteen male SD rats, 3 weeks old and SPF grade, were randomly divided into a control group (n=4) and a mandibular osteosarcoma group (n=10). Using tissue block transplantation, UMR106 cell-induced tumor tissues were transplanted subcutaneously into the left mandibular marrow cavity of the SD rats. Observations included behavioral changes, weight variations, tumor growth, and tumor formation rate. Bone changes were monitored via micro-CT scanning, and histological analysis was conducted using HE staining.</p><p><strong>Results: </strong>Two weeks post-transplantation, the mandibular osteosarcoma group exhibited significant left facial swelling, malocclusion, eating difficulties, and weight loss compared to the control group. The tumor formation rate was 80% (8/10). Micro-CT scans indicated significant bone destruction in the osteosarcoma group. HE staining revealed high cellular atypia and pathological mitoses in both subcutaneous and mandibular osteosarcoma cells, with no notable abnormalities in lung tissues.</p><p><strong>Conclusion: </strong>Tissue block transplantation is a viable method to establish a mandibular osteosarcoma model in SD rats. This method is simple, with a high tumor formation rate, providing an ideal animal model for mandibular osteosarcoma research.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2665-2671"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. PSMA PET/CT 诊断前列腺癌结节转移的准确性。
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13769
Pietro Pepe, Ludovica Pepe, Vincenzo Fiorentino, Mara Curduman, Michele Pennisi, Filippo Fraggetta

Background/aim: This study aimed to evaluate the diagnostic accuracy of prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) in pelvic nodal staging, using postoperative histopathology data as the reference standard.

Patients and methods: From January 2020 to June 2024, 78 patients with clinically significant prostate cancer (PCa) (ISUP Grade Group 2) underwent radical prostatectomy plus extended pelvic lymph node dissection (ePLND): 60 (77%) vs. 18 (23%) men had an intermediate vs. high risk PCa. All the patients underwent PSMA PET/TC before surgery for clinical staging and nodes focal uptake (standardized uptake value "SUVmax) was evaluated to rule out the presence of metastases.

Results: PSMA PET/CT was suspicious for nodes metastases in 16/78 (20.5%) men (median SUVmax 26.2), conversely, histology demonstrated nodes metastases in 18/78 (23.1%). PSMA PET/CT was negative for nodal involvement in all Grade Group 2 (GG2) PCa, positive in 4/4 (100%) GG3 PCa, and in 10/14 (71.4%) GG5 PCa. In detail, PSMA PET/CT was false negative in 2/4 PCa, characterized by GG5 plus ductal adenocarcinoma. Overall, PSMA PET/CT sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy in diagnosing nodal metastases were equal to 87.5, 96.8, 87.5 96.7, and 92.3%, respectively.

Conclusion: PSMA PET/CT demonstrated an overall diagnostic accuracy of 92.3% in nodal staging (100% in GG2 PCa), which decreased to 63.6% in GG5 PCa. In high-risk patients or in case of ductal adenocarcinoma, a negative PSMA PET/CT does not rule out the need for ePLND.

背景/目的:本研究旨在评估前列腺特异性膜抗原(PSMA)引导的正电子发射断层扫描/计算机断层扫描(PET/CT)在盆腔结节分期中的诊断准确性,以术后组织病理学数据作为参考标准:2020年1月至2024年6月,78名临床症状明显的前列腺癌(PCa)患者(ISUP 2级组)接受了根治性前列腺切除术加盆腔淋巴结清扫术(ePLND):60名(77%)与18名(23%)男性患者的前列腺癌属于中度风险与高度风险。所有患者都在手术前接受了PSMA PET/TC检查,以进行临床分期,并对结节灶摄取(标准化摄取值 "SUVmax")进行评估,以排除转移灶的存在:结果:16/78(20.5%)名男性患者的 PSMA PET/CT 怀疑有结节转移(中位 SUVmax 为 26.2),相反,18/78(23.1%)名患者的组织学检查显示有结节转移。PSMA PET/CT 在所有 2 级(GG2)PCa 中的结节受累情况为阴性,在 4/4 例(100%)GG3 PCa 和 10/14 例(71.4%)GG5 PCa 中为阳性。具体而言,2/4 的 PCa 为 PSMA PET/CT 假阴性,特点是 GG5 加导管腺癌。总的来说,PSMA PET/CT 在诊断结节转移方面的敏感性、特异性、阳性和阴性预测值以及诊断准确性分别为 87.5%、96.8%、87.5%、96.7% 和 92.3%:PSMA PET/CT 对结节分期的总体诊断准确率为 92.3%(在 GG2 PCa 中为 100%),而在 GG5 PCa 中则降至 63.6%。在高危患者或导管腺癌患者中,PSMA PET/CT 阴性并不能排除 ePLND 的必要性。
{"title":"PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases.","authors":"Pietro Pepe, Ludovica Pepe, Vincenzo Fiorentino, Mara Curduman, Michele Pennisi, Filippo Fraggetta","doi":"10.21873/invivo.13769","DOIUrl":"10.21873/invivo.13769","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to evaluate the diagnostic accuracy of prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) in pelvic nodal staging, using postoperative histopathology data as the reference standard.</p><p><strong>Patients and methods: </strong>From January 2020 to June 2024, 78 patients with clinically significant prostate cancer (PCa) (ISUP Grade Group 2) underwent radical prostatectomy plus extended pelvic lymph node dissection (ePLND): 60 (77%) vs. 18 (23%) men had an intermediate vs. high risk PCa. All the patients underwent PSMA PET/TC before surgery for clinical staging and nodes focal uptake (standardized uptake value \"SUVmax) was evaluated to rule out the presence of metastases.</p><p><strong>Results: </strong>PSMA PET/CT was suspicious for nodes metastases in 16/78 (20.5%) men (median SUVmax 26.2), conversely, histology demonstrated nodes metastases in 18/78 (23.1%). PSMA PET/CT was negative for nodal involvement in all Grade Group 2 (GG2) PCa, positive in 4/4 (100%) GG3 PCa, and in 10/14 (71.4%) GG5 PCa. In detail, PSMA PET/CT was false negative in 2/4 PCa, characterized by GG5 plus ductal adenocarcinoma. Overall, PSMA PET/CT sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy in diagnosing nodal metastases were equal to 87.5, 96.8, 87.5 96.7, and 92.3%, respectively.</p><p><strong>Conclusion: </strong>PSMA PET/CT demonstrated an overall diagnostic accuracy of 92.3% in nodal staging (100% in GG2 PCa), which decreased to 63.6% in GG5 PCa. In high-risk patients or in case of ductal adenocarcinoma, a negative PSMA PET/CT does not rule out the need for ePLND.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2880-2885"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective Analysis of Factors Influencing the Hemoglobin Level-increasing Effect of Sodium-glucose Co-transporter-2 Inhibitors. 影响钠-葡萄糖协同转运体-2 抑制剂提高血红蛋白水平效果的因素回顾分析
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13756
Yuki Yoshida, Harumi Yamada, Junya Sato

Background/aim: In several studies, Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been reported to increase hemoglobin (Hb) levels. In a study in which Hb levels were compared between patients who received SGLT2i and dipeptidyl peptidase-4 inhibitors, some patients exhibited increased Hb levels (>1.0 g/dl), whereas some exhibited unchanged Hb levels. Notably, several factors may influence the Hb-increasing effect of SGLT2i. This study aimed to analyze the factors influencing the Hb-increasing effect of SGLT2i.

Patients and methods: Type 2 diabetes patients were divided into three groups: SGLT2i (SGLT2i only group, n=36), those receiving a combination of SGLT2i and angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) (SGLT2i+ACEi/ARBs group, n=32), and those not receiving these drugs (control group, n=49). We retrospectively analyzed Hb changes in these groups. Kaplan-Meier curves compared Hb changes from SGLT2i initiation to day 63, with an Hb increase defined as ≥0.5 g/dl. In addition, sex, age, ACEi/ARBs, estimated glomerular filtration rate, and hematocrit levels were analyzed using Cox proportional hazards as factors influencing Hb-increasing events.

Results: Hb-increasing event rates were 61%, 41%, and 20% in the SGLT2i only, SGLT2i+ACEi/ARBs, and control groups, respectively. The Kaplan-Meier curves showed significantly higher Hb-increasing event rates in the SGLT2i only group than in the control and SGLT2i+ACEi/ARBs groups. In the Cox proportional hazards model, ACEi/ARBs use was associated with a 39% reduction in the incidence of Hb-increasing events.

Conclusion: SGLT2i exhibit a Hb-increasing effect, which may be reduced by ACEi/ARBs.

背景/目的:多项研究报告称,钠-葡萄糖共转运体-2 抑制剂(SGLT2i)可提高血红蛋白(Hb)水平。一项研究比较了接受 SGLT2i 和二肽基肽酶-4 抑制剂治疗的患者的血红蛋白水平,结果显示,一些患者的血红蛋白水平升高(>1.0 g/dl),而另一些患者的血红蛋白水平保持不变。值得注意的是,多种因素可能会影响 SGLT2i 增加血红蛋白的作用。本研究旨在分析影响 SGLT2i 增加血红蛋白作用的因素:2 型糖尿病患者分为三组:方法:将 2 型糖尿病患者分为三组:SGLT2i 组(仅 SGLT2i 组,n=36),接受 SGLT2i 和血管紧张素转换酶抑制剂(ACEi)或血管紧张素受体阻滞剂(ARBs)联合治疗的患者(SGLT2i+ACEi/ARBs 组,n=32),以及未接受上述药物治疗的患者(对照组,n=49)。我们对这些组别的血红蛋白变化进行了回顾性分析。Kaplan-Meier 曲线比较了从开始使用 SGLT2i 到第 63 天的血红蛋白变化,血红蛋白增加定义为≥0.5 g/dl。此外,还使用 Cox 比例危险度分析了性别、年龄、ACEi/ARBs、估计肾小球滤过率和血细胞比容水平等影响 Hb 增加事件的因素:仅使用 SGLT2i 组、SGLT2i+ACEi/ARBs 组和对照组的 Hb 增加事件发生率分别为 61%、41% 和 20%。Kaplan-Meier 曲线显示,仅使用 SGLT2i 组的 Hb 增加事件发生率明显高于对照组和 SGLT2i+ACEi/ARBs 组。在 Cox 比例危险模型中,使用 ACEi/ARBs 可使血红蛋白增加事件的发生率降低 39%:结论:SGLT2i 有增加血红蛋白的作用,而 ACEi/ARBs 可减少这种作用。
{"title":"Retrospective Analysis of Factors Influencing the Hemoglobin Level-increasing Effect of Sodium-glucose Co-transporter-2 Inhibitors.","authors":"Yuki Yoshida, Harumi Yamada, Junya Sato","doi":"10.21873/invivo.13756","DOIUrl":"10.21873/invivo.13756","url":null,"abstract":"<p><strong>Background/aim: </strong>In several studies, Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been reported to increase hemoglobin (Hb) levels. In a study in which Hb levels were compared between patients who received SGLT2i and dipeptidyl peptidase-4 inhibitors, some patients exhibited increased Hb levels (>1.0 g/dl), whereas some exhibited unchanged Hb levels. Notably, several factors may influence the Hb-increasing effect of SGLT2i. This study aimed to analyze the factors influencing the Hb-increasing effect of SGLT2i.</p><p><strong>Patients and methods: </strong>Type 2 diabetes patients were divided into three groups: SGLT2i (SGLT2i only group, n=36), those receiving a combination of SGLT2i and angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) (SGLT2i+ACEi/ARBs group, n=32), and those not receiving these drugs (control group, n=49). We retrospectively analyzed Hb changes in these groups. Kaplan-Meier curves compared Hb changes from SGLT2i initiation to day 63, with an Hb increase defined as ≥0.5 g/dl. In addition, sex, age, ACEi/ARBs, estimated glomerular filtration rate, and hematocrit levels were analyzed using Cox proportional hazards as factors influencing Hb-increasing events.</p><p><strong>Results: </strong>Hb-increasing event rates were 61%, 41%, and 20% in the SGLT2i only, SGLT2i+ACEi/ARBs, and control groups, respectively. The Kaplan-Meier curves showed significantly higher Hb-increasing event rates in the SGLT2i only group than in the control and SGLT2i+ACEi/ARBs groups. In the Cox proportional hazards model, ACEi/ARBs use was associated with a 39% reduction in the incidence of Hb-increasing events.</p><p><strong>Conclusion: </strong>SGLT2i exhibit a Hb-increasing effect, which may be reduced by ACEi/ARBs.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2767-2773"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral 5-aminolevulinic Acid for Patients With Localized Prostate Cancer Undergoing Low-dose-rate Brachytherapy: AMBER Trial. 口服 5-aminolevulinic Acid 用于接受低剂量近距离放射治疗的局部前列腺癌患者:AMBER 试验。
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13794
Makito Miyake, Nobumichi Tanaka, Kenta Ohnishi, Yasushi Nakai, Satoshi Anai, Kaoru Yamaki, Isao Asakawa, Nobutaka Nishimura, Tomomi Fujii, Fumiaki Isohashi, Kiyohide Fujimoto

Background/aim: Radiotherapy is one of the most frequently used options for prostate cancer (PCa). However, adverse effects related to irradiation of surrounding normal organs are significant clinical concerns. Specifically, genitourinary toxicity can dramatically reduce the quality of life. This clinical trial investigated the efficacy of oral 5-aminolevulinic acid phosphate combined with sodium ferrous citrate (ALA-SFC) in patients treated with low-dose-rate brachytherapy (LDR-BT) using an iodine-125 seed source.

Patients and methods: The AMBER study was a prospective single-center trial involving patients with localized PCa who underwent LDR-BT without external-beam radiotherapy (jRCTs051190077). Fifty patients were included and instructed to take capsules of ALA-SFC twice a day (200 mg phosphate salt and 229.42 mg per day) for six months from the day of seed implantation (prescribed radiation dose of 160 Gy). Patient data were collected before implantation, during ALA-SFC treatment, and at 1, 3, 6, 9, and 12 months post-LDR-BT. The primary endpoint of this trial was urinary frequency at three months. Other patient-reported outcomes, investigator-reported adverse events, and oncological outcomes were secondary endpoints.

Results: Of 50 enrolled cases (45 in the per-protocol analysis, 49 in the safety analysis), urinary frequency and its increase from baseline did not differ from 141 historical controls at any time point, including at three months post-LDR-BT. Propensity score matched analysis confirmed no time-course differences in frequency, volume, or urinary symptom scores between groups. Biochemical failure-free and metastasis-free survival also remained similar.

Conclusion: Oral supplementation of ALA-SFC to LDR-BT did not alleviate radiation-induced toxicity or improve oncological outcomes.

背景/目的:放疗是治疗前列腺癌(PCa)最常用的方法之一。然而,与照射周围正常器官相关的不良反应是临床上的重大问题。特别是泌尿生殖系统的毒性会大大降低患者的生活质量。这项临床试验研究了口服5-氨基乙酰丙酸磷酸盐联合枸橼酸亚铁钠(ALA-SFC)对使用碘-125种子源进行低剂量率近距离放射治疗(LDR-BT)患者的疗效:AMBER研究是一项前瞻性单中心试验,涉及接受LDR-BT而未接受体外放射治疗的局部PCa患者(jRCTs051190077)。研究共纳入了 50 名患者,并指导他们在种子植入(规定的放射剂量为 160 Gy)之日起的 6 个月内,每天两次服用 ALA-SFC 胶囊(每次 200 毫克磷酸盐,每次 229.42 毫克)。在植入前、ALA-SFC 治疗期间、LDR-BT 后 1、3、6、9 和 12 个月收集患者数据。该试验的主要终点是三个月后的尿频。其他患者报告的结果、研究者报告的不良事件和肿瘤结果为次要终点:在 50 例入组病例中(45 例进行了协议分析,49 例进行了安全性分析),在任何时间点(包括 LDR-BT 术后三个月),尿频及其与基线相比的增长与 141 例历史对照组相比均无差异。倾向得分匹配分析证实,不同组间在尿频、尿量或泌尿系统症状评分方面没有时间上的差异。无生化故障和无转移生存率也保持相似:结论:在 LDR-BT 中口服补充 ALA-SFC 不会减轻辐射引起的毒性,也不会改善肿瘤预后。
{"title":"Oral 5-aminolevulinic Acid for Patients With Localized Prostate Cancer Undergoing Low-dose-rate Brachytherapy: AMBER Trial.","authors":"Makito Miyake, Nobumichi Tanaka, Kenta Ohnishi, Yasushi Nakai, Satoshi Anai, Kaoru Yamaki, Isao Asakawa, Nobutaka Nishimura, Tomomi Fujii, Fumiaki Isohashi, Kiyohide Fujimoto","doi":"10.21873/invivo.13794","DOIUrl":"10.21873/invivo.13794","url":null,"abstract":"<p><strong>Background/aim: </strong>Radiotherapy is one of the most frequently used options for prostate cancer (PCa). However, adverse effects related to irradiation of surrounding normal organs are significant clinical concerns. Specifically, genitourinary toxicity can dramatically reduce the quality of life. This clinical trial investigated the efficacy of oral 5-aminolevulinic acid phosphate combined with sodium ferrous citrate (ALA-SFC) in patients treated with low-dose-rate brachytherapy (LDR-BT) using an iodine-125 seed source.</p><p><strong>Patients and methods: </strong>The AMBER study was a prospective single-center trial involving patients with localized PCa who underwent LDR-BT without external-beam radiotherapy (jRCTs051190077). Fifty patients were included and instructed to take capsules of ALA-SFC twice a day (200 mg phosphate salt and 229.42 mg per day) for six months from the day of seed implantation (prescribed radiation dose of 160 Gy). Patient data were collected before implantation, during ALA-SFC treatment, and at 1, 3, 6, 9, and 12 months post-LDR-BT. The primary endpoint of this trial was urinary frequency at three months. Other patient-reported outcomes, investigator-reported adverse events, and oncological outcomes were secondary endpoints.</p><p><strong>Results: </strong>Of 50 enrolled cases (45 in the per-protocol analysis, 49 in the safety analysis), urinary frequency and its increase from baseline did not differ from 141 historical controls at any time point, including at three months post-LDR-BT. Propensity score matched analysis confirmed no time-course differences in frequency, volume, or urinary symptom scores between groups. Biochemical failure-free and metastasis-free survival also remained similar.</p><p><strong>Conclusion: </strong>Oral supplementation of ALA-SFC to LDR-BT did not alleviate radiation-induced toxicity or improve oncological outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"3091-3105"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Triglyceride Levels on the Long-term Clinical Outcomes in Patients With Acute Myocardial Infarction. 甘油三酯水平对急性心肌梗死患者长期临床疗效的影响
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13792
Kazufumi Kato, Hiroaki Yokoyama, Toshihiro Iwasaki, Yuki Konno, Ken Yamazaki, Shun Shikanai, Tomo Kato, Michiko Tsushima, Maiko Senoo, Noritomo Narita, Hiroaki Ichikawa, Shuji Shibutani, Kenji Hanada, Hirofumi Tomita

Background/aim: Hypertriglyceridemia is a known cardiovascular risk factor. However, the relationship between serum triglyceride (TG) levels and the clinical outcomes in patients with acute myocardial infarction (AMI) is unclear.

Patients and methods: We conducted a single-center, retrospective observational study involving 538 consecutive patients with AMI who underwent emergent percutaneous coronary intervention within 12 hours of onset. Patients were categorized into three groups based on their serum TG levels at admission as follows: T1 group (TG <78 mg/dl, n=172), T2 group (78≤TG<141 mg/dl, n=177), and T3 group (141 mg/dl ≤TG, n=176). The primary endpoint was major adverse cardiovascular events (MACEs) defined as a composite of cardiovascular death, non-fatal MI, and non-fatal stroke. The median follow-up period was 2.4 (1.5-4.2) years.

Results: Patients in the T1 group were older, had a higher proportion of females, and had fewer cardiovascular risk factors. However, they also had a higher prevalence of multi-vessel coronary artery disease and severely calcified culprit lesions. The T1 group had a significantly higher rate of MACEs (20.4% in T1, 12.4% in T2 and 8.5% in T3, p<0.05 by Log-rank test, respectively). Multivariate analysis revealed that T1 was an independent predictor of MACEs (hazard ratio=2.19, 95% confidence interval=1.16-4.14, p<0.05).

Conclusion: Although patients with AMI with low TG levels at admission had fewer coronary risk factors, they had more severe calcified culprit lesions and worse clinical outcomes.

背景/目的:高甘油三酯血症是一种已知的心血管风险因素。然而,急性心肌梗死(AMI)患者血清甘油三酯(TG)水平与临床预后之间的关系尚不清楚:我们进行了一项单中心回顾性观察研究,研究涉及 538 名在发病 12 小时内接受急诊经皮冠状动脉介入治疗的连续急性心肌梗死患者。根据患者入院时的血清 TG 水平将其分为以下三组:T1 组(TG 结果:T1 组患者年龄较大,女性比例较高,心血管风险因素较少。但是,他们患有多支冠状动脉疾病和严重钙化的冠状动脉病变的比例也更高。T1 组的 MACE 发生率明显更高(T1 组为 20.4%,T2 组为 12.4%,T3 组为 8.5%,p 结论:虽然入院时总胆固醇水平较低的急性心肌梗死患者冠状动脉危险因素较少,但他们的罪魁祸首病变钙化程度更严重,临床预后更差。
{"title":"Impact of Triglyceride Levels on the Long-term Clinical Outcomes in Patients With Acute Myocardial Infarction.","authors":"Kazufumi Kato, Hiroaki Yokoyama, Toshihiro Iwasaki, Yuki Konno, Ken Yamazaki, Shun Shikanai, Tomo Kato, Michiko Tsushima, Maiko Senoo, Noritomo Narita, Hiroaki Ichikawa, Shuji Shibutani, Kenji Hanada, Hirofumi Tomita","doi":"10.21873/invivo.13792","DOIUrl":"10.21873/invivo.13792","url":null,"abstract":"<p><strong>Background/aim: </strong>Hypertriglyceridemia is a known cardiovascular risk factor. However, the relationship between serum triglyceride (TG) levels and the clinical outcomes in patients with acute myocardial infarction (AMI) is unclear.</p><p><strong>Patients and methods: </strong>We conducted a single-center, retrospective observational study involving 538 consecutive patients with AMI who underwent emergent percutaneous coronary intervention within 12 hours of onset. Patients were categorized into three groups based on their serum TG levels at admission as follows: T1 group (TG <78 mg/dl, n=172), T2 group (78≤TG<141 mg/dl, n=177), and T3 group (141 mg/dl ≤TG, n=176). The primary endpoint was major adverse cardiovascular events (MACEs) defined as a composite of cardiovascular death, non-fatal MI, and non-fatal stroke. The median follow-up period was 2.4 (1.5-4.2) years.</p><p><strong>Results: </strong>Patients in the T1 group were older, had a higher proportion of females, and had fewer cardiovascular risk factors. However, they also had a higher prevalence of multi-vessel coronary artery disease and severely calcified culprit lesions. The T1 group had a significantly higher rate of MACEs (20.4% in T1, 12.4% in T2 and 8.5% in T3, p<0.05 by Log-rank test, respectively). Multivariate analysis revealed that T1 was an independent predictor of MACEs (hazard ratio=2.19, 95% confidence interval=1.16-4.14, p<0.05).</p><p><strong>Conclusion: </strong>Although patients with AMI with low TG levels at admission had fewer coronary risk factors, they had more severe calcified culprit lesions and worse clinical outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"3078-3084"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Hydrogen Therapy in Aneurysmal SAH With RA and Newly-diagnosed SLE, Complicated With Acute Ischemic Infarction: A Case Report of Improved Immune Markers Including Tr1 Cells, Breg Cells and TIM3 Expression on Tc Cells. 分子氢疗法在伴有 RA 和新诊断的系统性红斑狼疮并发急性缺血性脑梗死的动脉瘤性 SAH 中的应用:关于免疫标记物(包括 Tr1 细胞、Breg 细胞和 Tc 细胞上的 TIM3 表达)改善的病例报告。
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13799
Jing-Yuan Chen, Jeng-Wei Lu, Shao-Wei Feng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Feng-Cheng Liu

Background/aim: Most nontraumatic subarachnoid hemorrhages (SAHs) are caused by ruptured saccular aneurysms, often resulting in a devastating clinical event characterized by high mortality and significant morbidity among survivors. Numerous studies have confirmed the neuroprotective effects of the molecular hydrogen due to its unique biological properties.

Case report: We present the case of a 44-year-old female with aneurysmal SAH with rheumatoid arthritis (RA) and newly diagnosed systemic lupus erythematosus (SLE), complicated by acute ischemic infarction. Despite surgical, pharmacological and non-pharmacological interventions, including embolization of the aneurysm, immunosuppressant, non-vitamin K antagonist oral anticoagulant (NOAC), and plasmapheresis, loss of consciousness continued. The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to negative. Her clinical symptoms stabilized without adverse effects.

Conclusion: This case highlights the potential benefits of molecular hydrogen therapy in managing aneurysmal SAH with underlying autoimmune disease, warranting further research.

背景/目的:大多数非创伤性蛛网膜下腔出血(SAH)都是由囊状动脉瘤破裂引起的,通常会导致破坏性的临床事件,其特点是死亡率高,幸存者发病率高。大量研究证实,分子氢具有独特的生物特性,具有神经保护作用:我们报告了一例 44 岁女性动脉瘤性 SAH 患者,她患有类风湿性关节炎(RA)和新诊断的系统性红斑狼疮(SLE),并伴有急性缺血性脑梗塞。尽管采取了手术、药物和非药物干预措施,包括动脉瘤栓塞、免疫抑制剂、非维生素K拮抗剂口服抗凝剂(NOAC)和血浆置换术,但意识丧失仍在继续。患者开始每天服用氢胶囊,结果 Treg 细胞和 Breg 细胞增加,Tc 细胞上的 TIM3+ 表达增加,抗dsDNA 由阳性转为阴性。她的临床症状趋于稳定,没有出现不良反应:本病例强调了分子氢疗法在治疗伴有潜在自身免疫性疾病的动脉瘤性 SAH 中的潜在益处,值得进一步研究。
{"title":"Molecular Hydrogen Therapy in Aneurysmal SAH With RA and Newly-diagnosed SLE, Complicated With Acute Ischemic Infarction: A Case Report of Improved Immune Markers Including Tr1 Cells, Breg Cells and TIM3 Expression on Tc Cells.","authors":"Jing-Yuan Chen, Jeng-Wei Lu, Shao-Wei Feng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Feng-Cheng Liu","doi":"10.21873/invivo.13799","DOIUrl":"10.21873/invivo.13799","url":null,"abstract":"<p><strong>Background/aim: </strong>Most nontraumatic subarachnoid hemorrhages (SAHs) are caused by ruptured saccular aneurysms, often resulting in a devastating clinical event characterized by high mortality and significant morbidity among survivors. Numerous studies have confirmed the neuroprotective effects of the molecular hydrogen due to its unique biological properties.</p><p><strong>Case report: </strong>We present the case of a 44-year-old female with aneurysmal SAH with rheumatoid arthritis (RA) and newly diagnosed systemic lupus erythematosus (SLE), complicated by acute ischemic infarction. Despite surgical, pharmacological and non-pharmacological interventions, including embolization of the aneurysm, immunosuppressant, non-vitamin K antagonist oral anticoagulant (NOAC), and plasmapheresis, loss of consciousness continued. The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to negative. Her clinical symptoms stabilized without adverse effects.</p><p><strong>Conclusion: </strong>This case highlights the potential benefits of molecular hydrogen therapy in managing aneurysmal SAH with underlying autoimmune disease, warranting further research.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"3131-3137"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Medicinal Efficacy of Alkaline Extract of Pine Seed Shell: Anti-UVC Activity and Macrophage Activation. 松籽壳碱性提取物的潜在药效:抗紫外线活性和巨噬细胞活化
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13739
Alejandro Mena Acra, Shin Uota, Masaaki Yoshihara, Yukio Murakami, Hiroshi Sakagami

Background/aim: Alkaline extracts of several plants which contain lignin degradation products have several unique biological activities. In order to search for new biological activities of alkaline extracts of pine seed shell (APs), their anti-ultraviolet C (UVC) and macrophage stimulation activity were investigated.

Materials and methods: Anti-UVC activity was determined by the ratio of the 50% cytotoxic concentration against human melanoma cell line COLO679 to the 50% UVC-protective concentration. Extracellularly secreted nitrite (NO2 -) by unstimulated and lipopolysaccharide (LPS)-stimulated mouse macrophage-like cells RAW264.7 was determined by Griess method.

Results: APs showed significantly higher anti-UVC activity than previously reported hot-water extracts of medical herbs. Anti-UVC activity of AP and vanillic acid was maintained for much longer than that of sodium ascorbate and vanillin. APs enhanced the production of NO2 - to the level induced by LPS. Simultaneous addition of AP and LPS did not further increase NO2 - production, suggesting their mechanisms of action overlap.

Conclusion: The present study suggests the possible application of APs as UVC protectors and immunopotentiators via macrophage activation.

背景/目的:含有木质素降解产物的多种植物的碱性提取物具有多种独特的生物活性。为了寻找松籽壳碱性提取物(APs)的新生物活性,研究了其抗紫外线C(UVC)和刺激巨噬细胞的活性:抗紫外线活性根据对人类黑色素瘤细胞株 COLO679 的 50%细胞毒性浓度与 50%紫外线保护浓度之比来确定。用 Griess 法测定未受刺激和受脂多糖(LPS)刺激的小鼠巨噬细胞 RAW264.7 分泌的亚硝酸盐(NO2 -):结果表明:AP 的抗 UVC 活性明显高于之前报道的药材热水提取物。与抗坏血酸钠和香兰素相比,AP 和香兰素的抗紫外线活性维持时间更长。APs 能增强 NO2 的产生,使其达到 LPS 诱导的水平。同时添加 AP 和 LPS 不会进一步增加 NO2 的产生,这表明它们的作用机制是重叠的:本研究表明,通过激活巨噬细胞,AP 可用作紫外线保护剂和免疫促进剂。
{"title":"Potential Medicinal Efficacy of Alkaline Extract of Pine Seed Shell: Anti-UVC Activity and Macrophage Activation.","authors":"Alejandro Mena Acra, Shin Uota, Masaaki Yoshihara, Yukio Murakami, Hiroshi Sakagami","doi":"10.21873/invivo.13739","DOIUrl":"10.21873/invivo.13739","url":null,"abstract":"<p><strong>Background/aim: </strong>Alkaline extracts of several plants which contain lignin degradation products have several unique biological activities. In order to search for new biological activities of alkaline extracts of pine seed shell (APs), their anti-ultraviolet C (UVC) and macrophage stimulation activity were investigated.</p><p><strong>Materials and methods: </strong>Anti-UVC activity was determined by the ratio of the 50% cytotoxic concentration against human melanoma cell line COLO679 to the 50% UVC-protective concentration. Extracellularly secreted nitrite (NO<sub>2</sub> <sup>-</sup>) by unstimulated and lipopolysaccharide (LPS)-stimulated mouse macrophage-like cells RAW264.7 was determined by Griess method.</p><p><strong>Results: </strong>APs showed significantly higher anti-UVC activity than previously reported hot-water extracts of medical herbs. Anti-UVC activity of AP and vanillic acid was maintained for much longer than that of sodium ascorbate and vanillin. APs enhanced the production of NO<sub>2</sub> <sup>-</sup> to the level induced by LPS. Simultaneous addition of AP and LPS did not further increase NO<sub>2</sub> <sup>-</sup> production, suggesting their mechanisms of action overlap.</p><p><strong>Conclusion: </strong>The present study suggests the possible application of APs as UVC protectors and immunopotentiators via macrophage activation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2629-2638"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colon Cancer With Bladder Invasion: A Single Center Experience. 结肠癌伴膀胱侵犯:单中心经验
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13782
Tzu-Wei Chiang, Li-Wen Chang, Feng-Fan Chiang, Jian-Ri Li, Sheng-Chun Hung

Background/aim: The aim of our study was to investigate the outcome of colon cancer with bladder invasion after surgical intervention.

Patients and methods: Between 2011 and 2022, a total of 41 patients diagnosed with colon cancer and bladder invasion underwent surgical procedures at Taichung Veterans General Hospital. The impact of various risk factors on overall survival (OS) was assessed using Kaplan-Meier analyses and Cox proportional hazards models.

Results: Among the enrolled patients, 21 underwent radical cystectomy, while 20 underwent partial cystectomy. Twelve had tumors located in the rectum, 19 in the sigmoid colon, and 10 in both the rectum and sigmoid colon. The median OS was 71.8 months in stage 2, 50.8 months in stage 3, and 11.2 months in stage 4 (p=0.061). Median OS was 71.8 months in patients with negative surgical margins and 10.5 months in those with positive surgical margins (p=0.003). In multivariate regression analysis, positive surgical margins [hazard ratio (HR)=3.64, 95% confidence interval (CI)=1.28-10.34, p=0.015] and emergency operations (HR=4.57, 95%CI=1.34-15.55, p=0.015) significantly impacted OS.

Conclusion: Complete resection of colon cancer with bladder invasion can yield excellent oncologic outcomes. The decision between partial and radical cystectomy should balance surgical margin clearance and the preservation of quality of life. Both surgical margin involvement and emergency operations are independent risk factors for OS.

背景/目的:我们的研究旨在探讨结肠癌合并膀胱侵犯的手术治疗效果:2011年至2022年间,台中荣民总医院共收治了41例结肠癌合并膀胱癌患者。采用Kaplan-Meier分析和Cox比例危险模型评估了各种风险因素对总生存期(OS)的影响:入组患者中,21人接受了根治性膀胱切除术,20人接受了部分膀胱切除术。12例肿瘤位于直肠,19例位于乙状结肠,10例位于直肠和乙状结肠。2期患者的中位生存期为71.8个月,3期为50.8个月,4期为11.2个月(P=0.061)。手术切缘阴性患者的中位生存期为 71.8 个月,手术切缘阳性患者的中位生存期为 10.5 个月(P=0.003)。在多变量回归分析中,手术切缘阳性[危险比(HR)=3.64,95%置信区间(CI)=1.28-10.34,P=0.015]和急诊手术(HR=4.57,95%CI=1.34-15.55,P=0.015)对OS有显著影响:结论:完全切除膀胱侵犯的结肠癌可获得良好的肿瘤治疗效果。在决定部分切除还是根治性膀胱切除术时,应在手术切缘清除和保持生活质量之间取得平衡。手术边缘受累和急诊手术都是影响OS的独立危险因素。
{"title":"Colon Cancer With Bladder Invasion: A Single Center Experience.","authors":"Tzu-Wei Chiang, Li-Wen Chang, Feng-Fan Chiang, Jian-Ri Li, Sheng-Chun Hung","doi":"10.21873/invivo.13782","DOIUrl":"10.21873/invivo.13782","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of our study was to investigate the outcome of colon cancer with bladder invasion after surgical intervention.</p><p><strong>Patients and methods: </strong>Between 2011 and 2022, a total of 41 patients diagnosed with colon cancer and bladder invasion underwent surgical procedures at Taichung Veterans General Hospital. The impact of various risk factors on overall survival (OS) was assessed using Kaplan-Meier analyses and Cox proportional hazards models.</p><p><strong>Results: </strong>Among the enrolled patients, 21 underwent radical cystectomy, while 20 underwent partial cystectomy. Twelve had tumors located in the rectum, 19 in the sigmoid colon, and 10 in both the rectum and sigmoid colon. The median OS was 71.8 months in stage 2, 50.8 months in stage 3, and 11.2 months in stage 4 (p=0.061). Median OS was 71.8 months in patients with negative surgical margins and 10.5 months in those with positive surgical margins (p=0.003). In multivariate regression analysis, positive surgical margins [hazard ratio (HR)=3.64, 95% confidence interval (CI)=1.28-10.34, p=0.015] and emergency operations (HR=4.57, 95%CI=1.34-15.55, p=0.015) significantly impacted OS.</p><p><strong>Conclusion: </strong>Complete resection of colon cancer with bladder invasion can yield excellent oncologic outcomes. The decision between partial and radical cystectomy should balance surgical margin clearance and the preservation of quality of life. Both surgical margin involvement and emergency operations are independent risk factors for OS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2990-3001"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnostic Potential of Extracellular Vesicles Derived From the Blood Plasma of Glioblastoma Patients. 从胶质母细胞瘤患者血浆中提取的细胞外小泡的诊断潜力
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13752
Katja Döring, Vesna Malinova, Christoph Bettag, Veit Rohde, Matthias Schulz, Kerstin Menck, Annalen Bleckmann, Claudia Binder, Judith Büntzel

Background/aim: Biomarkers for patients suffering from glioblastoma (GBM) are scarce. Extracellular vesicles (EV) are a promising candidate for a potential biomarker. Therefore, EV concentration could be a potential biomarker of tumor burden, volume, and prognosis.

Patients and methods: Large EV (lEV) and small EV (sEV) were isolated from 36 GBM patients' blood plasma by differential centrifugation. Nanoparticle tracking was used to measure EV concentration. Quantitative analysis of tumor volume was performed by evaluating T2/FLAIR relaxation times.

Results: The mean size of lEV was 173.3 nm ± 18.2 nm, while sEV measured 148.3 ± 9.0 nm. Patients with higher lEV concentrations showed a trend towards longer overall survival (36.1 vs. 16.5 months, p=0.08). Regarding inflammatory markers, higher leukocyte count was positively correlated with higher sEV concentration (r2=0.3887, DF 21, p=0.0015). No significant relationship was found between lEV or sEV concentration and tumor volume.

Conclusion: Overall EV concentration in the peripheral blood is not a predictor of tumor volume. sEV concentration is associated with a potential pro-inflammatory metabolism.

背景/目的:胶质母细胞瘤(GBM)患者的生物标记物非常稀缺。细胞外囊泡(EV)是一种有希望成为潜在生物标志物的候选物质。因此,EV浓度可作为肿瘤负荷、体积和预后的潜在生物标志物:通过差速离心法从36名GBM患者的血浆中分离出大EV(lEV)和小EV(sEV)。采用纳米粒子追踪技术测量EV浓度。通过评估T2/FLAIR弛豫时间对肿瘤体积进行定量分析:结果:lEV的平均大小为173.3 nm ± 18.2 nm,而sEV的大小为148.3 ± 9.0 nm。lEV浓度越高的患者总生存期越长(36.1个月对16.5个月,P=0.08)。在炎症指标方面,较高的白细胞计数与较高的 sEV 浓度呈正相关(r2=0.3887,DF 21,p=0.0015)。lEV或sEV浓度与肿瘤体积无明显关系:结论:外周血中的总体 EV 浓度不能预测肿瘤体积。
{"title":"The Diagnostic Potential of Extracellular Vesicles Derived From the Blood Plasma of Glioblastoma Patients.","authors":"Katja Döring, Vesna Malinova, Christoph Bettag, Veit Rohde, Matthias Schulz, Kerstin Menck, Annalen Bleckmann, Claudia Binder, Judith Büntzel","doi":"10.21873/invivo.13752","DOIUrl":"10.21873/invivo.13752","url":null,"abstract":"<p><strong>Background/aim: </strong>Biomarkers for patients suffering from glioblastoma (GBM) are scarce. Extracellular vesicles (EV) are a promising candidate for a potential biomarker. Therefore, EV concentration could be a potential biomarker of tumor burden, volume, and prognosis.</p><p><strong>Patients and methods: </strong>Large EV (lEV) and small EV (sEV) were isolated from 36 GBM patients' blood plasma by differential centrifugation. Nanoparticle tracking was used to measure EV concentration. Quantitative analysis of tumor volume was performed by evaluating T2/FLAIR relaxation times.</p><p><strong>Results: </strong>The mean size of lEV was 173.3 nm ± 18.2 nm, while sEV measured 148.3 ± 9.0 nm. Patients with higher lEV concentrations showed a trend towards longer overall survival (36.1 vs. 16.5 months, p=0.08). Regarding inflammatory markers, higher leukocyte count was positively correlated with higher sEV concentration (r<sup>2</sup>=0.3887, DF 21, p=0.0015). No significant relationship was found between lEV or sEV concentration and tumor volume.</p><p><strong>Conclusion: </strong>Overall EV concentration in the peripheral blood is not a predictor of tumor volume. sEV concentration is associated with a potential pro-inflammatory metabolism.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2735-2739"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three-dimensional Patient-specific Quality Assurance Using Beam Delivery Log Data for Pencil Beam Scanning Carbon-ion Radiotherapy. 利用铅笔束扫描碳离子放疗的光束传输日志数据进行三维患者特定质量保证。
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.21873/invivo.13776
Masaaki Takashina, Masashi Yagi, Yuuki Noguchi, Taku Nakaji, Noriaki Hamatani, Toshiro Tsubouchi, Tatsuaki Kanai

Background/aim: In the pencil beam scanning carbon-ion radiotherapy, spot positions are arranged in three dimensions throughout the entire target region. Therefore, dose deviations can occur due to spot position errors in the target. However, performing three-dimensional measurements for routine patient-specific quality assurance (PSQA) is difficult because a simple measurement method has not been established. This study aimed to establish a three-dimensional dose verification method using beam delivery log data.

Materials and methods: Pencil beam dose distributions in water were generated through Monte Carlo (MC) calculations. Treatment beam dose distribution was calculated by superposing the pencil beam dose distributions, considering given spot positions and monitor units (referred to as semi-MC, SMC). The aim of this study was to perform gamma analysis (GA) using dose distributions of log data-based SMC instead of measured dose for PSQA. To verify SMC, the SMC depth-dose curves were compared with the measured dose. To assess the equivalence between the proposed and measurement-based methods, pass rates of two-dimensional GA were compared. Furthermore, a three-dimensional GA was performed to investigate clinically suitable criteria.

Results: The SMC dose curves were consistent with measured dose, with a deviation <5%. In two-dimensional GA, pass rates for the proposed method were generally lower than those for measurement-based method. The results of the three-dimensional GA indicated that the proposed method, with criteria of 3%-3 mm and 3%-2 mm, had capabilities comparable to the measurement-based method.

Conclusion: The developed three-dimensional log data-based PSQA method with criteria of 3%-3 mm and 3%-2 mm is clinically applicable.

背景/目的:在铅笔束扫描碳离子放射治疗中,整个靶区的光点位置都是三维排列的。因此,靶点位置误差会导致剂量偏差。然而,由于尚未建立一种简单的测量方法,因此很难进行常规患者特定质量保证(PSQA)的三维测量。本研究旨在利用射束传输记录数据建立一种三维剂量验证方法:通过蒙特卡洛(MC)计算生成水中的铅笔束剂量分布。考虑到给定的光斑位置和监测单元(称为半 MC,SMC),通过叠加铅笔束剂量分布来计算治疗束剂量分布。本研究的目的是使用基于对数数据的 SMC 剂量分布代替 PSQA 的测量剂量,进行伽马分析(GA)。为了验证 SMC,将 SMC 深度-剂量曲线与测量剂量进行了比较。为了评估建议方法和基于测量的方法之间的等效性,比较了二维 GA 的通过率。此外,还进行了三维 GA,以研究适合临床的标准:结果:SMC剂量曲线与测量剂量一致,但存在偏差:所开发的基于三维对数数据的 PSQA 方法以 3%-3 毫米和 3%-2 毫米为标准,适用于临床。
{"title":"Three-dimensional Patient-specific Quality Assurance Using Beam Delivery Log Data for Pencil Beam Scanning Carbon-ion Radiotherapy.","authors":"Masaaki Takashina, Masashi Yagi, Yuuki Noguchi, Taku Nakaji, Noriaki Hamatani, Toshiro Tsubouchi, Tatsuaki Kanai","doi":"10.21873/invivo.13776","DOIUrl":"10.21873/invivo.13776","url":null,"abstract":"<p><strong>Background/aim: </strong>In the pencil beam scanning carbon-ion radiotherapy, spot positions are arranged in three dimensions throughout the entire target region. Therefore, dose deviations can occur due to spot position errors in the target. However, performing three-dimensional measurements for routine patient-specific quality assurance (PSQA) is difficult because a simple measurement method has not been established. This study aimed to establish a three-dimensional dose verification method using beam delivery log data.</p><p><strong>Materials and methods: </strong>Pencil beam dose distributions in water were generated through Monte Carlo (MC) calculations. Treatment beam dose distribution was calculated by superposing the pencil beam dose distributions, considering given spot positions and monitor units (referred to as semi-MC, SMC). The aim of this study was to perform gamma analysis (GA) using dose distributions of log data-based SMC instead of measured dose for PSQA. To verify SMC, the SMC depth-dose curves were compared with the measured dose. To assess the equivalence between the proposed and measurement-based methods, pass rates of two-dimensional GA were compared. Furthermore, a three-dimensional GA was performed to investigate clinically suitable criteria.</p><p><strong>Results: </strong>The SMC dose curves were consistent with measured dose, with a deviation <5%. In two-dimensional GA, pass rates for the proposed method were generally lower than those for measurement-based method. The results of the three-dimensional GA indicated that the proposed method, with criteria of 3%-3 mm and 3%-2 mm, had capabilities comparable to the measurement-based method.</p><p><strong>Conclusion: </strong>The developed three-dimensional log data-based PSQA method with criteria of 3%-3 mm and 3%-2 mm is clinically applicable.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2935-2944"},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
In vivo
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1